Abstract: The invention relates to the preparation and use of ?,?-unsaturated aldehyde of hyaluronan having a double bond in the positions 4 and 5 and an aldehydic group in the position 6 of the glucosamine part of the polysaccharide. The method of preparation is based on dehydration of hyaluronan having an aldehydic group in the position 6 of the glucosamine part of the polysaccharide. Two methods have been described, which are dehydration in a solution or heating in solid state in absence of solvents, bases or other additives. This derivative allows stabilization of conjugates of hyaluronan with amino compounds by means of a multiple bond from the aldehyde side, and therefore, it is possible to effectively immobilize practically any compound containing an amino group to such modified hyaluronan in physiological conditions. In case of using a diamine or compounds or polymers containing three or more amino groups, it is possible to prepare crosslinked hyaluronan derivatives.
Type:
Grant
Filed:
August 5, 2013
Date of Patent:
December 20, 2016
Assignee:
Contipro Biotech s.r.o.
Inventors:
Radovan Buffa, Petra Sedova, Vladimir Velebny, Lucie Wolfova, Ivana Basarabova, Robert Pospisil, Martina Hasova, Kristina Nesporova
Abstract: A phosphorylated A2A receptor agonist providing agonist properties on the A2A receptor after dephosphorylation the phosphorylated A2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5?-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e.g. inflammatory events. In particular, compounds of formula (I) are also disclosed.
Type:
Grant
Filed:
December 16, 2013
Date of Patent:
November 29, 2016
Assignee:
Crozet Medical GmbH
Inventors:
Jurgen Schrader, Christa Muller, Ali El-Tayeb, Jamshed Iqbal
Abstract: A means for selectively removing ET under coexistence of a substance showing a negative charge, such as nucleic acid is described. Endotoxin is selectively removed by bringing a polymer obtained by crosslinking cyclodextrin with an isocyanate-based crosslinking agent in contact with a solution containing endotoxin and the substance showing the negative charge such as nucleic acid.
Type:
Grant
Filed:
May 29, 2013
Date of Patent:
November 29, 2016
Assignees:
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, JNC CORPORATION
Abstract: A pharmaceutical composition for intranasal administration for human subjects includes vitamin B12 and a pharmaceutically acceptable carrier. The vitamin B12 particles are dispersed in a hydrophobic continuous phase as the pharmaceutically acceptable carrier. The dispersion of solid vitamin B12 particles (crystals or amorphic) in a hydrophobic continuous phase displays very satisfactory bioavailability. Also, the intense red color is reduced significantly, making the pharmaceutical composition acceptable for intranasal use.
Abstract: There is provided a method for the preparation of an N,N,N-trialkylaminopolymer having one or more unsubstituted heteroatoms different from nitrogen atom. The method comprises a first step of alkylating an aminopolymer to produce an N,N-dialkylaminopolymer, wherein substantially no N,N,N-trialkylaminopolymer is produced; and a second step of alkylating the N,N-diaminopolymer to produce the N,N,N-trialkylaminopolymer. The N,N,N-trialkylaminopolymer is produced with a satisfactory degree of quaternization and with only a low percentage of the unsubstituted heteroatoms alkylated. The N,N,N-trialkylaminopolymer can be an N,N,N-trialkylaminopolysaccharide or an N,N,N-trialkylchitosan such as N,N,N-trimethylchitosan.
Abstract: The present invention provides a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, a pharmaceutical composition comprising the same, and uses thereof in the preparation of medicaments for treating diabetes, wherein substituents R1-R7 are as defined in the specification. The present invention also provides a method for synthesizing the phenyl C-glucoside derivative containing a deoxyglucose structure and an intermediate product. The method has advantages of being simple to manage and of low cost, which is suitable for large-scale industrial production. The present invention further provides a cocrystal of (1S)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-D-glucose and L-proline, and preparation method and uses thereof.
Type:
Grant
Filed:
December 5, 2013
Date of Patent:
November 29, 2016
Assignee:
Tianjin Institute of Pharmaceutical Research
Abstract: The present invention provides a method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells comprising the step: extracting LPS from the cell culture in a composition (LPS extraction composition) comprising water, an alcohol and a further organic solvent.
Type:
Grant
Filed:
January 8, 2015
Date of Patent:
November 22, 2016
Assignee:
GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventors:
Philippe Charles, Geoffroy Geldhof, Vincent Mancuso
Abstract: A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using an eluent comprising potassium or caesium ions, (b) recovery of the solute from the eluted solution, (c) diafiltration of an aqueous solution of the recovered solute, and (d) second diafiltration after the addition of 1 M NaCl, and recovering GM1. The purity level of GM1 obtained is higher than 99.0%.
Abstract: An alginate monomer structure with metal crystallite embedded includes a first alginate monomer and at least a first metal crystallite. The first alginate monomer is composed of a first uronate molecule and a second uronate molecule, which are linked linearly to each other. A first carbonyl group is formed on a second carbon atom (C2) of the main ring in the first uronate molecule, a carboxyl group is presented on a sixth carbon atom (C6) of the main ring in the second uronate molecule, and a first intramonomer glycosidic linkage is presented between a first carbon atom (C1) of the main ring in the first uronate molecule and a fourth carbon atom (C4) of the main ring in the second uronate molecule. The first metal crystallite is associated between the first uronate molecule and the second uronate molecule.
Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
Type:
Grant
Filed:
July 29, 2014
Date of Patent:
November 15, 2016
Assignee:
GENZYME CORPORATION
Inventors:
Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
Abstract: The present invention aims to provide a method for producing a polyrotaxane which enables industrially advantageous production of a polyrotaxane with a high inclusion rate.
Type:
Grant
Filed:
September 9, 2013
Date of Patent:
November 8, 2016
Assignees:
Sumitomo Seika Chemicals Co., Ltd., Advanced Softmaterials Inc.
Abstract: The present invention is synergistic antibiotic compositions having pH adjusted profiles for manufacturing combination, and administration, particularly for patients at risk or suffering from ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic compositions containing fosfomycin and aminoglycosides having individually predetermined and selected pH ranges are manufactured and stored for in combination prior to aerosolization, preferably with a specially designed in-line nebulizer attached to a ventilator.
Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.
Type:
Grant
Filed:
May 4, 2012
Date of Patent:
November 1, 2016
Assignee:
TRUSTEES OF BOSTON UNIVERSITY
Inventors:
James J. Collins, Kyle R. Allison, Mark P. Brynildsen
Abstract: Method for preparing a branched glucan having a chain comprising a plurality of glucose units linked by alpha 1,4-glycoside bonds and a plurality of side-groups linked to said chain via another type of glycoside bonding, which side-groups comprise one or more glucose units, the method comprising contacting a glucose source with a polysaccharide—which polysaccharide is a glucan comprising a plurality of glucose units linked by alpha 1,4-glycoside bonds and is essentially linear or branched to a lesser extent than the branched glucan that is to be prepared—in the presence of an acid catalyst under polycondensation conditions, thereby forming the branched glucan.
Type:
Grant
Filed:
May 21, 2013
Date of Patent:
November 1, 2016
Assignee:
NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO
Inventors:
Maurice Karel Hubertina Essers, Johannes Wilhelmus Timmermans, Jerome Villarama Diaz, Ronald Tako Marinus van den Dool, Theodoor Maximiliaan Slaghek
Abstract: The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate.
Type:
Grant
Filed:
May 8, 2014
Date of Patent:
October 18, 2016
Assignee:
Genzyme Corporation
Inventors:
Yunxiang Zhu, Seng H. Cheng, Canwen Jiang, Luis Z. Avila
Abstract: Objects are to provide an additive for a feed which can improve growth performance and meat quality of livestock, and can improve palatability of the feed, a feed and a method for preparing the feed, and the objects can be solved by an additive for a feed which comprises at least one or two or more of a polyphenol derived from EFB, ?-tocopherol derived from EFB and xyloses derived from EFB, a feed which comprises an additive for a feed being added to a formulating material for a feed in the range of 0.05 to 20% by weight with a dry basis, and a method for preparing the feed.
Abstract: A wound dressing comprises a wound dressing substrate including one or more of gas vesicles, rhamnolipids, and sophorolipids. The wound dressing can be fabric-based or hydrogel-based. Methods for producing a wound dressing are also provided.
Abstract: An object of the present invention is to provide a novel polysaccharide derivative used for a separating agent for optical isomers. The novel polysaccharide derivative contains a structure in which a hydrogen atom of a hydroxyl group or an amino group at the 2-position in a structural unit of the polysaccharide is substituted with a monovalent group represented by the following general formula (1), and a hydrogen atom of a hydroxyl group or an amino group at the 3-position in the structural unit is substituted with a monovalent group represented by the following general formula (2): R1—NH—CO—??(1) R2—NH—CO—??(2) where R1 and R2 represent substituted or unsubstituted aryl groups which are different from each other.
Abstract: The present invention discloses a method for preparing high purity paeoniflorin and albiflorin simultaneously comprising: extraction the raw material Paeonia Lactiflora by percolation or heating reflux to obtain the Paeonia Lactiflora extract solution, then purification by macroporous absorption resin, alumina column and silica gel column in turn to obtain high purity paeoniflorin and albiflorin. The preparation method of the invention can provide high purity paeoniflorin and albiflorin with low price and energy-consumption by the identical procedure. The process is simple. The purification efficacy is high and the purification time is short.
Abstract: Described herein are processes for the preparation of compounds of formula (I): and pharmaceutically acceptable salts, solvates, and hydrates thereof.
Type:
Grant
Filed:
October 23, 2008
Date of Patent:
September 27, 2016
Assignee:
CEMPRA PHARMACEUTICALS, INC.
Inventors:
David E. Pereira, Manish Kanchanbhai Patel, Keshav Deo